UnitedHealth Group Incorporated (NYSE:UNH) recent rally took place on significantly less volume which dipped to almost 2.3 million contracts on 15-Jul-18 versus its daily average of 2.65 million. The healthcare conglomerate reported $3.14 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.04 by $0.10. Royal Bank of Canada restated a "buy" rating on shares of UnitedHealth Group in a report on Wednesday, April 18th.
In the recent week UnitedHealth Group Incorporated stock price volatility was noted 1.05% while for the last month volatility was seen at 1.25%.
The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations.
Out of the important value indicator of stocks, EPS growth rate is most important.
UnitedHealth Group Incorporated (UNH) stock has been separated 12.93% away from the 200-day MA.
The stock, up almost 17 percent this year, fell 3.5 percent to $248. Company's EPS for the past five years is valued at 12.5%, leading it to an EPS value of 15.98% for the next five years.
UnitedHealth reported earnings per share of $3.14 for the second quarter of the year. This represents a $3.60 annualized dividend and a dividend yield of 1.39%. BofA/Merrill, on the other hand, Upgrade a from "Underperform " to " Neutral" rating on this stock in a research note dated Thursday, February 15th, 2018. This is a boost from UnitedHealth Group's previous quarterly dividend of $0.75. Buckingham Capital Mgmt has invested 0.81% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, UNH's EBITDA Margin is 14.47 whereas AES's is 7.48.
UNH has been the topic of a number of research reports. $275.50's average target is 6.49% above currents $258.7 stock price.
Taking a look at Earnings per Share, The AES Corporation tends to be beating the analyst estimates more than UnitedHealth Group Incorporated.so AES is more profitable than UNH. Following the completion of the transaction, the insider now owns 153,679 shares of the company's stock, valued at approximately $39,118,989.45. Twenty-seven analysts have rated the stock with a buy rating, The stock has a consensus rating of "Buy" and a consensus target price of $263.71. Finally, BMO Capital Markets raised their price target on shares of UnitedHealth Group from $275.00 to $285.00 and gave the company a buy rating in a research report on Thursday, June 7th. Buffington Mohr Mcneal holds 0.2% in UnitedHealth Group Incorporated (NYSE:UNH) or 2,500 shares. On Thursday, April 19 the insider Shine Kenneth Irwin sold $47,959. The share price has already crossed its 20 days moving average, floating at a distance of 2.81% and sits 5.08% higher versus its 50 days moving average. The sale was made public in a document filed with the SEC. Shares for $3.73M were sold by BURKE RICHARD T on Monday, May 21. This repurchase authorization permits the healthcare conglomerate to buy shares of its stock through open market purchases. The disclosure for this sale can be found here.
The insurer earned $3.14 a share on revenue of $56.09 billion.
Since January 18, 2018, it had 0 insider purchases, and 11 insider sales for $30.17 million activity.
UnitedHealth Group Inc, the largest US health insurer, on Tuesday reported second-quarter medical costs slightly higher than Wall Street expectations, sending its shares down 4 percent and weighing on the rest of the sector. The fund owned 13,911 shares of the healthcare conglomerate's stock after buying an additional 1,061 shares during the period.
Health insurance is the biggest revenue generator for UnitedHealth.
UnitedHealth's net earnings attributable to shareholders rose almost 28 percent to $2.92 billion in the quarter ended June 30. The California-based Ssi Mngmt has invested 0.07% in UnitedHealth Group Incorporated (NYSE:UNH). The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx.